Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Lancet (London, England)
|
June 9, 2018
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara, Mustafa Özgüroğlu, Yung-Jue Bang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2016
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
F Stephen Hodi, Wen-Jen Hwu, Richard Kefford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 16, 2015
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik, S Peter Kang, Drew Rasco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2018
Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Richard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 19, 2016
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I Daud, Jedd D Wolchok, Caroline Robert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2018
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Richard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Lancet (London, England)
|
July 19, 2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert, Antoni Ribas, Jedd D Wolchok, et al.
JAMA Oncology
|
September 4, 2020
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara, Eric Van Cutsem, Yung-Jue Bang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2020
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima, Manish A Shah, Kei Muro, et al.
The New England Journal of Medicine
|
June 4, 2013
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
Omid Hamid, Caroline Robert, Adil Daud, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Lancet (London, England)
|
June 9, 2018
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara, Mustafa Özgüroğlu, Yung-Jue Bang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2016
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
F Stephen Hodi, Wen-Jen Hwu, Richard Kefford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 16, 2015
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik, S Peter Kang, Drew Rasco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2018
Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Richard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 19, 2016
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I Daud, Jedd D Wolchok, Caroline Robert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2018
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Richard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Lancet (London, England)
|
July 19, 2014
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert, Antoni Ribas, Jedd D Wolchok, et al.
JAMA Oncology
|
September 4, 2020
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara, Eric Van Cutsem, Yung-Jue Bang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 7, 2020
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima, Manish A Shah, Kei Muro, et al.
The New England Journal of Medicine
|
June 4, 2013
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
Omid Hamid, Caroline Robert, Adil Daud, et al.
Page
of 3